AstraZeneca (LSE: AZN) has set out one of the most ambitious growth plans in global pharma: roughly doubling total revenue to about $80bn by 2030. That target rests on three pillars working simultaneously — a broad drug pipeline, a $50bn US investment push, and continued deep exposure to China, legal complications and all. 2026 is shaping up as the year the company has to start actually proving it.

The Quick Version

  • AstraZeneca is targeting around $80bn total revenue by 2030, roughly double its 2023 base, via about 20 planned new medicine launches.
  • It's pledged $50bn of US manufacturing and R&D investment by 2030, alongside a $15bn commitment in China.
  • China remains its largest emerging market, but a legal case involving a former executive and the local subsidiary adds real uncertainty.
  • In early 2026 AstraZeneca added a direct New York Stock Exchange listing while keeping London as its primary market.
  • FY2025 total revenue came in around $58.7bn, up about 8% — leaving a large gap still to close toward the 2030 target.

The Science Pillar: A Genuinely Broad Pipeline

AstraZeneca has built out a wide oncology portfolio — antibody-drug conjugates and targeted therapies developed alone and with partners — alongside respiratory, cardiovascular and rare-disease franchises strengthened by the Alexion acquisition. FY2025 results, published February 2026, highlighted a run of positive late-stage trial readouts and a growing number of medicines reaching blockbuster-scale sales.

The company is also pushing into big new territory — obesity, hypertension and other chronic conditions — where the commercial prizes are huge but competition is fierce. Success here could underpin growth well beyond 2030, but a handful of pivotal trial readouts can swing the outlook sharply in either direction.

The US Pillar: $50bn and a New Listing

The US is AstraZeneca's single largest market, and the $50bn investment pledge through 2030 is meant to expand American production and research capacity, including a major new facility geared toward next-generation chronic-disease and weight-management treatments.

At the start of 2026, AstraZeneca completed a direct NYSE listing of its ordinary shares under ticker AZN, withdrawing its American depositary shares from Nasdaq. This was framed as harmonising the listing structure across London, Nasdaq Stockholm and New York — not a relocation. London stays the primary listing, which matters given earlier speculation the company might shift its main listing across the Atlantic.

The China Pillar: Scale, but Also a Legal Cloud

China remains one of AstraZeneca's most important markets — 2025 China sales were around $5.5bn, though growth slowed to roughly 4% from earlier double-digit rates. The $15bn investment commitment shows management still sees the country as central to its strategy, even as conditions get tougher.

Those tougher conditions include disclosed legal proceedings: Chinese prosecutors brought charges against AstraZeneca's local subsidiary and former executives, including a former senior China leader, over allegations relating to personal-information handling and medicine importation, with separate fraud allegations against former executives too. AstraZeneca has said it prepaid an amount of unpaid taxes on certain imported cancer treatments; no trial date has been set. These remain allegations, and the legal process is ongoing.

Volume-based procurement — centralised tendering that drives down prices on established medicines — has also squeezed margins on older products, while local Chinese biotech competitors have grown more capable.

Why This Matters Beyond AstraZeneca Itself

AstraZeneca is one of the most valuable companies on the London market and a major index constituent, so its trajectory matters directly to pension funds, tracker funds and everyday UK investors. A company aiming to roughly double revenue over a decade, while spending tens of billions across continents, is effectively betting on sustained scientific and commercial delivery at genuinely large scale.

The decision to keep London primary while broadening US investor access is being read as at least partial confidence in the City, at a time some large companies have looked to New York instead — symbolically important for UK policymakers trying to retain marquee listings.

Risks Worth Weighing

Pipeline setbacks are the most obvious risk: a strategy built on roughly 20 launches is vulnerable to trial failures, regulatory delays or disappointing uptake. US pricing pressure could squeeze margins even where products succeed, and patent expiries on established medicines mean new products are needed just to stand still. China adds a distinct layer — the legal proceedings, the local growth slowdown and the broader geopolitical backdrop all carry potential financial and reputational consequences that aren't yet resolved.

What to Watch Next

Late-stage trial readouts across oncology, cardiovascular and metabolic programmes; progress converting the $50bn US and $15bn China commitments into actual operating capacity and sales; updates on the Chinese legal case at each results announcement; and how the new NYSE listing plays out for trading volumes and the shareholder base over time.